Get started
NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1

NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0TDD trade ideas

Final Puke in Process - Wave 5We are approaching a strong trendline support level which begain back in 2017. The stock is heavily oversold, RSI is in a descending wedge pattern. We are also approaching the golden pocket Fibonacci retracement which can provide additional support. I expect a reaction at these levels and a breakout from the falling wedge pattern on the RSI. So far patience has been the best strategy, I do think this is the final Wave 5 of the correction and so this puke can continue a little further. It's hard to get the optimal entry on a falling knife, to play it safe you can await the wedge breakout with strong bullish volume. Not financial advise.
NYSE:NVOLong
by NoFOMO_
4
NVO presents an opportunityNVO has been getting absolutely slaughtered lately, I cannot help but be more bullish than ever on this. The stock falls deeper into the long-term demand zone. Stocks usually bottom on bad news, this is the market pricing the stock in as more and more bad news comes down the road. A final blow is given, and the market realizes the fundamentals do not match the price. This will happen for NVO. BBWP needs to cool off here, the stock needs to consolidate. Stochastic has reset.
NYSE:NVOLong
by Apollo_21mil
$NVO more pain ahead! Headed down to $46-55 - NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug. - With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results. - It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.
NYSE:NVOShort
by bigbull037
7
1/7/25 - $nvo - Probs a buy in low 80s... but...1/7/25 :: VROCKSTAR :: NYSE:NVO Probs a buy in low 80s... but... Friend who highlighted some good calls last year DM'd me (ty!) about this one. Figured i'd copy/paste my response in case anyone could add to this logic or is more knowledgeable on catalysts timing etc. 1/ i typically stay away from pharma (mainly bc i look at so many sectors and this is the singular one i've never covered professionally) 2/ the financials look great. growth, margins, cf generation - all "A" grade 3/ unclear how the NASDAQ:SAVA result will affect px performance in the coming days given diabetes seems to be a relevant part of the portfolio (but obviously this is a mega diversified name) so in short, it's defn a buy here, but given my conviction on maybe 5 other names that i can really size up, i've set an even greedier entry look closer to sub $80... not that i'd not own it here, but just i don't want to overcomplicate my book at the moment while i'm moving/ shaking aggressively on other stuff. 4/ also, what the banana hammock happened on dec 19 - unlocking that "event's bottom"/ implication looks like the key to determining how low this goes. it's already massively oversold, so if it wicks much further, it's simply a buy on mean reversion anyway - could probably pick up an easy 5+% under $80 without even trying (which is my lazy approach here). but i don't fault u if u own it - looks legit. 5/ options chain implying meager MT move keeps me wondering if this is dead money for the immediate term and i should only be a greedy buyer in the mid 70s. i think there's a way to generate yield here, but feels too risk adverse for my style (high octane) until i can gear it up at these lower levels with a better sense for mkt rippity-do-dah so - what do u think, anon? V
NYSE:NVOLong
by VROCKSTAR
NVO LongNovo Nordisk, a global leader in diabetes and obesity treatments, has traditionally maintained a solid financial standing with strong revenue growth, impressive profitability, and a robust pipeline of new treatments. However, the company has recently faced a significant dip in its stock price, largely due to market concerns related to its obesity treatment segment. While these concerns may reflect short-term volatility or market uncertainty, it’s important to recognize that the company's underlying fundamentals remain strong. When evaluating the company through the lens of intrinsic value indicators—such as discounted cash flow analysis, price-to-earnings ratios, and projected growth rates—Novo Nordisk appears to be trading at a favorable price relative to its long-term growth potential. This suggests that, despite the recent drop in stock price, the company’s shares may be undervalued, offering a potentially attractive entry point for investors who are willing to take a long-term view. In the long run, the obesity treatment market is expected to grow, and Novo Nordisk’s leadership in this space, along with its diversified portfolio and innovation-driven strategy, could well position it to benefit from future market developments. Therefore, the current stock price may present a buying opportunity for those who believe in the company’s continued strength and market leadership. #DYOR
NYSE:NVOLong
by zdmre
Novo Nordisk's The recent drop in Novo Nordisk's stock price is attributed to several factors. A key issue is the company’s struggle to meet the surging demand for its weight-loss drugs, such as Wegovy. Although demand remains strong, investors are concerned about Novo Nordisk's ability to scale up production and deliveries, which is creating downward pressure on the stock. Additionally, some recent financial results failed to meet Wall Street expectations. Despite revenue growth in key product categories, overall revenues in some reports came in below forecasts. This underperformance has contributed to a negative investor sentiment. However, analysts emphasize that Novo Nordisk's core products remain in high demand, and the company has significant long-term growth potential if it addresses its supply chain and production challenges
OMXCOP:NOVO_BLong
by ForexCompany
$NVO - gimme a POP LONGWassup folks, so: some of my ideas have proven to be correct and I'm watching others. NYSE:NVO has earnings approaching eom January. They have also experienced a sell off recently, however I think there's some potential for a pop to the upside... this underlying has some juice in it too, currently holding an IVR of 55%. There's some rich premium to be sold! Entering a put credit spread 01/31 selling the 88 strike and buying the 86 strike! Break even will be the sold put strike minus credit collected = $87.50 ish!, I'LL ALSO BE RUNNING A TIGHT STOP HERE... ANYTHING WITH A CLOSE BELOW $80 HANDLE IS AN OUT FOR ME
NYSE:NVOLong
by taekwone1
NVO highest conviction trade of the yearNVO has sold off brutally after breaking the macro momentum trend. This stock was indeed overheated but sold off even worse after a miss on projected weight loss percentage of a new med. We have hit the golden pocket correction. BBWP is maxed out, and stochastic RSI is bottoming. This is extremely overblown, this new med is not even adding to their already massive revenue. I expect NVO to hit well over 110$ this year as healthcare in general lags into uncertain markets. I love trading these gap style plays or massive over reaction sell offs. Novo Nordisk is one of the most fundamentally strong companies in the world. As SPX becomes even more expensive, investors will look internationally. My plan: Short term side ways I plan on layering into out of the money LEAPS, likely 110 as that will allow me to capture a lot of delta expansion
NYSE:NVOLong
by Apollo_21mil
NOVO has developed an H&S formationAs others have also mentioned on Trading View, NOVO has developed an H&S formation. The formation is to some extent supported by volume. Volume should be large when forming the left shoulder 1, as well as when forming the head 2, and when the price goes down at the right shoulder 4, but when forming the right shoulder the volume should be low 3. It is not. Since May, the volume balance has been negative, i.e. high volume at the price bottom and low volume at the price peak. At 794, there will be a significant break of 3%, especially if it is supported by high volume. There is no significant break yet. The object is heading towards 629. An H&S formation is a reversal formation. NOVO has been in a bullish trend, according to MA. However, the price is now below SMA 200. The price momentum indicators go from sell to buy within a month on Trading View. The price is well below a red cloud in Ichimocu. It is not possible to say now whether we will have a significant break down or whether the price will recover. The forecast will depend on this. Fundamentally, analysts are predominantly positive about the stock. Many companies would like to enter the obesity market, but there are far from good results in a phase 1 study to a finished drug, if it becomes a drug at all. Disclaimer: I have a relatively large position in the stock, which I bought when the shares plunged during the covid19 epidemic. I have sold 1/4 share when the price had tripled, so I am thinking of sitting still now even in the face of the technical picture - I am long. In the past, price has fluctuated between two pivot lines at times. Then I have swing traded NOVO. NB: Remember you must do your own research and assessment before buying and selling.
OMXCOP:NOVO_B
by scorpiris
1
Holy Cow, A lot of Big Option Purchases Coming In!First price target for January is $90 and it could happen soon. Be careful as spike downs tend to have a lower low formed prior to reversal, this would create bullish divergence on RSI, MACD and more which is another to double down. Options chain for calls expiring 1/10/2025 show the $90 strike has 1,522 calls bought on Friday at .87 per contract. Not huge, bot overall the bias on NVO is buy the dip. long term target of well over 100
NYSE:NVOLong
by LeapTrades
6
Novo Nordisk hit my target this week and I have started to buy The head and shoulders pattern successfully played out, with OMXCOP:NOVO_B reaching my full target at 670. Check out my original post: The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%. I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase OMXCOP:NOVO_B , first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
OMXCOP:NOVO_BLong
by madsroland
NOVO - 23% weight loss causes 23% price dropHead and Shoulders pattern complete, price drops from $148 to sub $80. The drop from the head of the pattern is 23%, we should now be in Wave 5 where the final drop is 23%. Cagrisema fat loss is 23% (below expectation of 25%). Wall St trims 23% off the stock price. Largest sell volume seen in the stock, going into the oversold territory - 19 RSI on Daily, most oversold it's been in over a decade. Possible support from the following confluence: 200 Week EMA, Golden Fibonacci pocket 0.618, possible end of 5th wave. Time to DCA, from $78 down to $58, for a 3-5 year hold. Not financial advice
NYSE:NVOLong
by NoFOMO_
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024): Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER). Operating Profit: Increased by 21% (DKK 91.6 billion). Net Profit: Rose 18% to DKK 72.8 billion. Product Highlights: Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion). Ozempic (Diabetes): Slight sales dip but remains a key contributor. Challenges: CagriSema Trial: Missed expected weight-loss targets, leading to stock decline. Outlook: Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER). Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
NYSE:NVOLong
by datavanza
Novo Nordisk (NVO): Beautiful Reversal Pattern is emerging Novo Nordisk price has charted a famous and beautiful reversal pattern - Head & Shoulders. We have 3 peaks with the middle one the tallest also called Head. The Right Shoulder inclines down so the magnitude of the bearish move is strong. The dotted line between valleys of the Head is called a Neckline. The bearish target for this reversal is located at the distance of Head's height subtracted from the breakdown point on the Neckline. So, the target is at $89. This area aligns very well with the bottom of last October and the peak of last May.
NYSE:NVO
by aibek
8
Novo completely oversold🐂 Trade Idea: Long - NOVO 🔥 Account Risk: 20.00% 📈 Recommended Product: Stock 🔍 Entry: +/- 750.00 🐿 DCA: No 😫 Stop-Loss: 675.00 🎯 Take-Profit #1: 1,000.00 (50%) 🎯 Trail Rest: Yes 🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ideas don’t work all the time no matter how good they look. Do not get a victim of FOMO, there is always another trade idea waiting. 🚨🚨🚨 If you like what you see don’t forget to leave a comment 💬 or smash that like ❤️ button! — Novo Nordisk is completely oversold (in fear of RFK) and so is the rest of the Pharma sector as well. Nevertheless, Novo is still printing money and trial results for a new product should come in end 24 or beginning 25 for the oral version of the weight loss drug. The fear over political decisions in the US should be used to buy the Pharma sector. For me, it is Novo and Regeneron. — Disclaimer & Disclosures pursuant to §34b WpHG The trades shown here related to stocks, cryptos, commodities, ETFs and funds are always subject to risks. All texts as well as the notes and information do not constitute investment advice or recommendations. They have been taken from publicly available sources to the best of our knowledge and belief. All information provided (all thoughts, forecasts, comments, hints, advice, stop loss, take profit, etc.) are for educational and private entertainment purposes only. Nevertheless, no liability can be assumed for the correctness in each individual case. Should visitors to this site adopt the content provided as their own or follow any advice given, they act on their own responsibility.
OMXCOP:NOVO_BLong
by LGNDRY-Capital
2
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation. The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges. Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
NYSE:NVOShort
by UDIS_View